Europe PMC
open access
Clinical considerations on the use of evinacumab for the treatment of homozygous familial hypercholesterolemia
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder that results in severely elevated low-density lipoprotein cholesterol (LDL-C) due to dysfunctional activity of the low-density lipoprotein receptor (LDLR) and impaired clearance of LDL-C. Individuals with HoFH require intensi
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia#857116
- Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia#1337647
- Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia#833259
- HoFH, the International Clinical Collaborators Registry#1292452
- Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy#1046368
Record · ID 1204001
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive